Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Blog Article

Editorial summary Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic Power and Hookup Cable for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle.Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end Chair and a Half protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.